|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
ATE346064T1
(de)
*
|
2000-09-15 |
2006-12-15 |
Vertex Pharma |
Pyrazolverbindungen als protein-kinasehemmer
|
|
US20020111353A1
(en)
*
|
2000-12-05 |
2002-08-15 |
Mark Ledeboer |
Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
|
|
ATE354573T1
(de)
*
|
2000-12-21 |
2007-03-15 |
Vertex Pharma |
ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
|
|
PE20021011A1
(es)
*
|
2001-03-23 |
2003-02-01 |
Bayer Corp |
Derivados quinazolinicos como inhibidores de la rho-quinasa
|
|
DE60227492D1
(de)
|
2001-04-10 |
2008-08-21 |
Merck & Co Inc |
Hemmstoffe der akt aktivität
|
|
US7105667B2
(en)
*
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
US7138404B2
(en)
*
|
2001-05-23 |
2006-11-21 |
Hoffmann-La Roche Inc. |
4-aminopyrimidine derivatives
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
WO2003026665A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
|
ATE495741T1
(de)
|
2001-09-26 |
2011-02-15 |
Pfizer Italia Srl |
Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
JP4237066B2
(ja)
*
|
2002-01-10 |
2009-03-11 |
エフ．ホフマン−ラ ロシュ アーゲー |
骨形成を増加させるための薬物の製造におけるＧＳＫ−３β阻害剤の使用
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
SG159380A1
(en)
*
|
2002-02-06 |
2010-03-30 |
Vertex Pharma |
Heteroaryl compounds useful as inhibitors of gsk-3
|
|
EP1485381B8
(en)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine as inhibitors of protein kinases
|
|
EP1485380B1
(en)
*
|
2002-03-15 |
2010-05-19 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines as inhibitors of protein kinases
|
|
US7091343B2
(en)
|
2002-03-15 |
2006-08-15 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
WO2003086394A1
(en)
|
2002-04-08 |
2003-10-23 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
EP1552842A1
(en)
|
2002-06-07 |
2005-07-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
WO2004009602A1
(en)
*
|
2002-07-23 |
2004-01-29 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
|
ATE451104T1
(de)
|
2002-07-29 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
|
|
CN1319968C
(zh)
*
|
2002-08-02 |
2007-06-06 |
沃泰克斯药物股份有限公司 |
用作gsk－3的抑制剂的吡唑组合物
|
|
SI1532145T1
(sl)
*
|
2002-08-02 |
2007-02-28 |
Vertex Pharma |
Pirazolni sestavki, koristni kot inhibitorji GSK-3
|
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
CN1678589A
(zh)
*
|
2002-09-05 |
2005-10-05 |
安万特医药股份有限公司 |
作为药物的新氨基吲唑衍生物与含有它们的药物组合物
|
|
AU2003255482A1
(en)
*
|
2002-10-02 |
2004-04-23 |
Merck Patent Gmbh |
Use of 4 amino-quinazolines as anti cancer agents
|
|
EP1558585B1
(en)
*
|
2002-10-04 |
2013-09-25 |
Prana Biotechnology Limited |
Neurologically-active compounds
|
|
KR100490893B1
(ko)
*
|
2002-10-11 |
2005-05-23 |
(주) 비엔씨바이오팜 |
2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
|
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
FR2847253B1
(fr)
*
|
2002-11-19 |
2007-05-18 |
Aventis Pharma Sa |
Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
US7309701B2
(en)
|
2002-11-19 |
2007-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
US7462613B2
(en)
|
2002-11-19 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
US7423148B2
(en)
|
2002-11-21 |
2008-09-09 |
Chiron Corporation |
Small molecule PI 3-kinase inhibitors and methods of their use
|
|
WO2004072029A2
(en)
*
|
2003-02-06 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridazines useful as inhibitors of protein kinases
|
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
WO2004087679A1
(en)
*
|
2003-04-01 |
2004-10-14 |
Aponetics Ag |
2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
|
|
US20060135541A1
(en)
*
|
2003-06-02 |
2006-06-22 |
Astrazeneca Ab |
(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
|
|
WO2004112719A2
(en)
|
2003-06-19 |
2004-12-29 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
CN1984660B
(zh)
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
GB0315966D0
(en)
*
|
2003-07-08 |
2003-08-13 |
Cyclacel Ltd |
Compounds
|
|
BRPI0412259B1
(pt)
|
2003-07-22 |
2019-08-20 |
Astex Therapeutics Limited |
Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
|
|
JP2007500179A
(ja)
*
|
2003-07-30 |
2007-01-11 |
サイクラセル・リミテッド |
キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
US20060024690A1
(en)
*
|
2003-09-19 |
2006-02-02 |
Kao H P |
Normalization of data using controls
|
|
US7417726B2
(en)
*
|
2003-09-19 |
2008-08-26 |
Applied Biosystems Inc. |
Normalization of data using controls
|
|
US20050221357A1
(en)
*
|
2003-09-19 |
2005-10-06 |
Mark Shannon |
Normalization of gene expression data
|
|
US20050124562A1
(en)
*
|
2003-09-23 |
2005-06-09 |
Joseph Guiles |
Bis-quinazoline compounds for the treatment of bacterial infections
|
|
KR20060123164A
(ko)
|
2003-10-17 |
2006-12-01 |
아스트라제네카 아베 |
암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
|
|
WO2005056547A2
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
|
RU2006124559A
(ru)
*
|
2003-12-09 |
2008-01-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов
|
|
EP1694686A1
(en)
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
|
US7534798B2
(en)
|
2004-02-11 |
2009-05-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
WO2005083105A2
(en)
*
|
2004-02-26 |
2005-09-09 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
|
|
CA2560111A1
(en)
*
|
2004-03-15 |
2005-09-22 |
Takeda Pharmaceutical Company Limited |
Aminophenylpropanoic acid derivative
|
|
JP4790703B2
(ja)
*
|
2004-04-07 |
2011-10-12 |
武田薬品工業株式会社 |
環式化合物
|
|
JP2007533717A
(ja)
*
|
2004-04-21 |
2007-11-22 |
アストラゼネカ アクチボラグ |
化合物
|
|
WO2005105788A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Indole derivatives and use thereof as kinase inhibitors
|
|
US7880000B2
(en)
*
|
2004-05-07 |
2011-02-01 |
Amgen Inc. |
Protein kinase modulators and method of use
|
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
|
SI1771450T1
(sl)
*
|
2004-05-14 |
2008-06-30 |
Millennium Pharm Inc |
Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
|
|
JP4993604B2
(ja)
*
|
2004-05-14 |
2012-08-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ
|
|
AU2012200416B2
(en)
*
|
2004-05-14 |
2014-07-31 |
Millennium Pharmaceuticals, Inc. |
"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
|
|
US20050255485A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Livak Kenneth J |
Detection of gene duplications
|
|
EP2261226B1
(en)
|
2004-05-14 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Methods for preparing aurora kinase inhibitors
|
|
JP2007538102A
(ja)
*
|
2004-05-20 |
2007-12-27 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体
|
|
KR20070034519A
(ko)
*
|
2004-05-27 |
2007-03-28 |
이 아이 듀폰 디 네모아 앤드 캄파니 |
광감성 중합체 보호층용 현상제
|
|
JP4990766B2
(ja)
*
|
2004-07-01 |
2012-08-01 |
シンタ ファーマシューティカルズ コーポレーション |
二置換型ヘテロアリール化合物
|
|
CN101031551A
(zh)
*
|
2004-07-06 |
2007-09-05 |
安吉永生物制药公司 |
针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
|
|
EP1778669A2
(en)
*
|
2004-08-18 |
2007-05-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
|
TW200624431A
(en)
*
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
|
EP1797047B1
(en)
*
|
2004-09-30 |
2012-01-25 |
Tibotec Pharmaceuticals |
Hiv inhibiting 5-substituted pyrimidines
|
|
MX2007003797A
(es)
*
|
2004-09-30 |
2007-04-23 |
Tibotec Pharm Ltd |
5-heterociclil pirimidinas inhibidoras del virus de inmunodeficiencia humana.
|
|
CA2573976C
(en)
*
|
2004-09-30 |
2014-04-29 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
|
ATE479687T1
(de)
*
|
2004-10-15 |
2010-09-15 |
Takeda Pharmaceutical |
Kinaseinhibitoren
|
|
PE20060600A1
(es)
*
|
2004-10-29 |
2006-07-14 |
Banyu Pharma Co Ltd |
Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
|
|
US7491720B2
(en)
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
|
WO2006050476A2
(en)
|
2004-11-03 |
2006-05-11 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as ion channel modulators and methods of use
|
|
MX2007005857A
(es)
|
2004-11-17 |
2007-10-10 |
Mikana Therapeutics Inc |
Inhibidores de cinasa.
|
|
WO2006068770A1
(en)
|
2004-11-24 |
2006-06-29 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
|
CA2588220A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Products Inc. |
Heteroaromatic derivatives useful as anticancer agents
|
|
US8110573B2
(en)
*
|
2004-12-30 |
2012-02-07 |
Astex Therapeutics Limited |
Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
|
|
EP1841760B1
(en)
|
2004-12-30 |
2011-08-10 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
EP2161275A1
(en)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
AR054425A1
(es)
*
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
EP1871765B1
(en)
*
|
2005-01-26 |
2009-12-09 |
Schering Corporation |
3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
|
|
NZ561145A
(en)
|
2005-02-04 |
2011-02-25 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
|
AU2006215386B2
(en)
|
2005-02-16 |
2009-06-11 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2006087538A1
(en)
*
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2006227790B2
(en)
*
|
2005-03-15 |
2009-09-10 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
JP2008534481A
(ja)
*
|
2005-03-23 |
2008-08-28 |
アストラゼネカ アクチボラグ |
インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン
|
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
|
DE602006002271D1
(de)
*
|
2005-04-05 |
2008-09-25 |
Astrazeneca Ab |
Pyrimidinderivate zur verwendung als antikrebsmittel
|
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
|
US7462639B2
(en)
|
2005-04-14 |
2008-12-09 |
Hoffmann-La Roche Inc. |
Aminopyrazole derivatives
|
|
JP2008540335A
(ja)
*
|
2005-04-27 |
2008-11-20 |
アストラゼネカ・アクチエボラーグ |
ピラゾリル・ピリミジン誘導体の疼痛治療における使用
|
|
JP5075624B2
(ja)
*
|
2005-04-28 |
2012-11-21 |
田辺三菱製薬株式会社 |
シアノピリジン誘導体及びその医薬としての用途
|
|
WO2006119504A2
(en)
|
2005-05-04 |
2006-11-09 |
Renovis, Inc. |
Fused heterocyclic compounds, and compositions and uses thereof
|
|
WO2006117212A2
(en)
|
2005-05-04 |
2006-11-09 |
Develogen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
US20080194606A1
(en)
*
|
2005-05-05 |
2008-08-14 |
Astrazeneca |
Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
|
|
US20080287437A1
(en)
*
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US7491732B2
(en)
|
2005-06-08 |
2009-02-17 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
|
JP5118029B2
(ja)
|
2005-06-14 |
2013-01-16 |
タイゲン バイオテクノロジー カンパニー，リミテッド |
ピリミジン化合物
|
|
EP1746096A1
(en)
|
2005-07-15 |
2007-01-24 |
4Sc Ag |
2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
|
|
CA2619517A1
(en)
*
|
2005-08-18 |
2007-02-22 |
Michael Mortimore |
Pyrazine kinase inhibitors
|
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
|
AU2006282896A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
UA96427C2
(en)
*
|
2005-09-30 |
2011-11-10 |
Мийкана Терапьютикс, Инк. |
Substituted pyrazole compounds
|
|
WO2007041358A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
RU2463302C2
(ru)
*
|
2005-10-28 |
2012-10-10 |
Астразенека Аб |
Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования
|
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス，インコーポレイティド |
神経発生のｇａｂａ受容体媒介調節
|
|
ATE521608T1
(de)
*
|
2005-11-01 |
2011-09-15 |
Array Biopharma Inc |
Glucokinaseaktivatoren
|
|
JP5249770B2
(ja)
*
|
2005-11-03 |
2013-07-31 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼインヒビターとして有用なアミノピリジン
|
|
CA2629781A1
(en)
*
|
2005-11-16 |
2007-05-24 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
US8546404B2
(en)
*
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
|
JP5474354B2
(ja)
|
2005-12-30 |
2014-04-16 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
|
US20080058312A1
(en)
*
|
2006-01-11 |
2008-03-06 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US7807672B2
(en)
*
|
2006-02-16 |
2010-10-05 |
Schering Corporation |
Compounds that are ERK inhibitors
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
PE20080145A1
(es)
*
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
|
BRPI0709690B8
(pt)
*
|
2006-03-30 |
2021-05-25 |
Janssen R & D Ireland |
5-amido pirimidinas substituídas e composição farmacêutica que as compreende
|
|
MX2008012482A
(es)
*
|
2006-03-31 |
2008-10-10 |
Abbott Lab |
Compuestos de indazol.
|
|
EP2574340A3
(en)
|
2006-04-07 |
2013-04-17 |
Novartis AG |
Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
|
|
NZ572591A
(en)
|
2006-04-14 |
2012-01-12 |
Prana Biotechnology Ltd |
3N-substituted 8-hydroxy-quinazolin-4-ones
|
|
EP2017279B1
(en)
*
|
2006-04-27 |
2013-09-04 |
Msd K.K. |
Aminopyrimidine derivatives having aurora-a-selective inhibitory activity
|
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
JP4401428B2
(ja)
|
2006-06-27 |
2010-01-20 |
武田薬品工業株式会社 |
縮合環化合物
|
|
WO2008001101A2
(en)
*
|
2006-06-29 |
2008-01-03 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JP5523829B2
(ja)
|
2006-06-29 |
2014-06-18 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
EP2036894A4
(en)
*
|
2006-06-30 |
2011-01-12 |
Kyowa Hakko Kirin Co Ltd |
AURORA INHIBITOR
|
|
UY30444A1
(es)
*
|
2006-06-30 |
2008-01-31 |
Astrazeneca Ab |
Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
|
|
CA2656290A1
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
|
WO2008021038A2
(en)
*
|
2006-08-09 |
2008-02-21 |
Millennium Pharmaceuticals, Inc. |
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
|
|
US7832809B2
(en)
*
|
2006-08-11 |
2010-11-16 |
Schlumberger Technology Corporation |
Degradation assembly shield
|
|
JP2008081492A
(ja)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
JP2010505961A
(ja)
*
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
JP2010505962A
(ja)
|
2006-10-09 |
2010-02-25 |
武田薬品工業株式会社 |
キナーゼ阻害剤
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008053812A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and medicinal use thereof
|
|
EP2086965B1
(en)
*
|
2006-11-02 |
2010-02-10 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
DE602007007985D1
(de)
*
|
2006-12-19 |
2010-09-02 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyrimidine
|
|
KR20090094073A
(ko)
*
|
2006-12-29 |
2009-09-03 |
티보텍 파마슈티칼즈 리미티드 |
Ｈｉｖ를 억제하는 6-치환된 피리미딘
|
|
CN101573342A
(zh)
*
|
2006-12-29 |
2009-11-04 |
泰博特克药品有限公司 |
抑制hiv的5,6-取代的嘧啶类化合物
|
|
KR20090108124A
(ko)
|
2007-02-06 |
2009-10-14 |
노파르티스 아게 |
Ｐｉ 3-키나제 억제제 및 그의 사용 방법
|
|
JPWO2008111441A1
(ja)
|
2007-03-05 |
2010-06-24 |
協和発酵キリン株式会社 |
医薬組成物
|
|
KR20090120510A
(ko)
*
|
2007-03-09 |
2009-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 아미노피리미딘
|
|
MX2009009592A
(es)
*
|
2007-03-09 |
2009-11-10 |
Vertex Pharma |
Aminopiridinas utiles como inhibidores de proteinas cinasas.
|
|
CA2679884A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
CA2682195A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
WO2008117050A1
(en)
*
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
|
CA2683785A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
WO2008129255A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Astrazeneca Ab |
5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
|
|
WO2008129380A1
(en)
|
2007-04-18 |
2008-10-30 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
|
JP5389786B2
(ja)
*
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害として有用なアミノピリミジン
|
|
AU2008247592A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
MX2009011811A
(es)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasa.
|
|
ATE521609T1
(de)
*
|
2007-05-04 |
2011-09-15 |
Astrazeneca Ab |
Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
CN101687852A
(zh)
*
|
2007-05-24 |
2010-03-31 |
沃泰克斯药物股份有限公司 |
可用作激酶抑制剂的噻唑类和吡唑类化合物
|
|
KR101294731B1
(ko)
*
|
2007-06-04 |
2013-08-16 |
삼성디스플레이 주식회사 |
어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
|
|
JP2010529193A
(ja)
*
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
|
JP2010532756A
(ja)
*
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
|
|
WO2009007753A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Astrazeneca Ab |
4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
|
|
KR20100038108A
(ko)
*
|
2007-07-25 |
2010-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
트리아진 키나제 억제제
|
|
WO2009013545A2
(en)
*
|
2007-07-26 |
2009-01-29 |
Astrazeneca Ab |
Chemical compounds
|
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2008282156B2
(en)
*
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
|
EP3078662A1
(en)
|
2007-09-21 |
2016-10-12 |
Array Biopharma, Inc. |
Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
ES2445444T3
(es)
|
2007-10-11 |
2014-03-03 |
Glaxosmithkline Llc |
Nuevos inhibidores de sEH y su uso
|
|
TW200942549A
(en)
|
2007-12-17 |
2009-10-16 |
Janssen Pharmaceutica Nv |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
|
|
US20090270418A1
(en)
*
|
2008-01-09 |
2009-10-29 |
Marianne Sloss |
Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
|
|
EP2242745A1
(de)
*
|
2008-02-07 |
2010-10-27 |
Sanofi-Aventis |
Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
ES2556353T3
(es)
|
2008-02-21 |
2016-01-15 |
Merck Sharp & Dohme Corp. |
Compuestos que son inhibidores de las ERK
|
|
WO2009104802A1
(en)
*
|
2008-02-22 |
2009-08-27 |
Banyu Pharmaceutical Co., Ltd. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
|
HUE025179T2
(en)
|
2008-04-21 |
2016-02-29 |
Taigen Biotechnology Co Ltd |
Heterocyclic Compounds
|
|
US8844033B2
(en)
|
2008-05-27 |
2014-09-23 |
The Trustees Of Columbia University In The City Of New York |
Systems, methods, and media for detecting network anomalies using a trained probabilistic model
|
|
AU2009259026B2
(en)
*
|
2008-06-11 |
2012-10-04 |
Astrazeneca Ab |
Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
|
|
US8470841B2
(en)
|
2008-07-09 |
2013-06-25 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
EP2318377B1
(en)
*
|
2008-07-31 |
2013-08-21 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
|
CN102215816A
(zh)
*
|
2008-09-03 |
2011-10-12 |
沃泰克斯药物股份有限公司 |
共晶和包含所述共晶的药物制剂
|
|
CN102405284B
(zh)
*
|
2008-09-05 |
2016-01-20 |
新基阿维罗米克斯研究公司 |
设计不可逆抑制剂的算法
|
|
CN102264728B
(zh)
*
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
RU2011116928A
(ru)
*
|
2008-09-30 |
2012-11-20 |
Астразенека Аб (Se) |
Гетероциклические ингибиторы jак киназы
|
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
|
WO2010056758A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
|
US9023834B2
(en)
|
2008-11-13 |
2015-05-05 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
JP5490137B2
(ja)
*
|
2008-12-19 |
2014-05-14 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
プロテインキナーゼ阻害薬としての二環式ピラゾール
|
|
JP5738196B2
(ja)
|
2008-12-22 |
2015-06-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
|
|
US8809343B2
(en)
|
2008-12-26 |
2014-08-19 |
Fudan University |
Pyrimidine derivative, preparation method and use thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
CN102395576A
(zh)
*
|
2009-02-27 |
2012-03-28 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
|
CA2660962A1
(en)
|
2009-03-31 |
2010-09-30 |
Astellas Pharma Inc. |
Novel pharmaceutical composition for treatment of schizophrenia
|
|
US8399663B2
(en)
|
2009-04-03 |
2013-03-19 |
Astellas Pharma Inc. |
Salt of 1,3,5-triazine-2,4,6-triamine derivative
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
JP2012529513A
(ja)
*
|
2009-06-08 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
トリアジン誘導体類及びそれらの治療応用
|
|
CA2764785C
(en)
*
|
2009-06-08 |
2015-10-27 |
California Capital Equity, Llc |
Triazine derivatives and their therapeutical applications
|
|
US20120178758A1
(en)
*
|
2009-06-09 |
2012-07-12 |
California Capital Equity, Llc |
Styryl-triazine derivatives and their therapeutical applications
|
|
US9078902B2
(en)
|
2009-06-09 |
2015-07-14 |
Nantbioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
BRPI1011527A2
(pt)
*
|
2009-06-09 |
2016-07-26 |
California Capital Equity Llc |
derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
|
|
US8877924B2
(en)
|
2009-06-09 |
2014-11-04 |
NantBio Inc. |
Benzyl substituted triazine derivatives and their therapeutical applications
|
|
CA2763730A1
(en)
*
|
2009-06-18 |
2010-12-23 |
Cellzome Limited |
Heterocyclylaminopyrimidines as kinase inhibitors
|
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β－類澱粉生成之化合物
|
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
|
ES2443016T3
(es)
|
2009-08-26 |
2014-02-17 |
Sanofi |
Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
|
|
EP2478361A4
(en)
*
|
2009-09-16 |
2014-05-21 |
Celgene Avilomics Res Inc |
CONJUGATES AND INHIBITORS OF PROTEIN KINASE
|
|
EP2467065B1
(en)
*
|
2009-11-13 |
2020-01-08 |
Intuitive Surgical Operations, Inc. |
End effector with redundant closing mechanisms
|
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
CN102812167A
(zh)
|
2009-12-30 |
2012-12-05 |
阿维拉制药公司 |
蛋白的配体-介导的共价修饰
|
|
SA111320200B1
(ar)
*
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
RU2012140021A
(ru)
|
2010-02-19 |
2014-03-27 |
Миллениум Фармасьютикалз, Инк. |
КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2571359A4
(en)
*
|
2010-05-20 |
2013-10-23 |
Merck Sharp & Dohme |
NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
|
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
|
HUE029196T2
(en)
|
2010-06-04 |
2017-02-28 |
Hoffmann La Roche |
Aminoprimidine derivatives as LRRK2 modulators
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
ME03085B
(me)
|
2010-07-29 |
2019-01-20 |
Oryzon Genomics Sa |
Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena
|
|
WO2012030910A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
JP5932794B2
(ja)
|
2010-09-01 |
2016-06-08 |
アムビト ビオスシエンセス コルポラチオン |
光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
|
|
US20120053176A1
(en)
*
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
CN103270030B
(zh)
*
|
2010-09-01 |
2016-01-20 |
埃姆比特生物科学公司 |
吡唑基氨基喹唑啉的氢溴酸盐
|
|
US20130225614A1
(en)
*
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
CA2810024A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
WO2012030944A2
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
BR112013011600B1
(pt)
|
2010-11-10 |
2022-01-11 |
Genentech, Inc |
Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2688883B1
(en)
|
2011-03-24 |
2016-05-18 |
Noviga Research AB |
Pyrimidine derivatives
|
|
JP2014524456A
(ja)
|
2011-08-25 |
2014-09-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
セリン／スレオニンｐａｋ１阻害剤
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
PE20141228A1
(es)
|
2011-09-22 |
2014-10-01 |
Pfizer |
Derivados de pirrolopirimidina y purina
|
|
MX342326B
(es)
|
2011-09-27 |
2016-09-26 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
WO2013092940A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
|
|
CN104203939B
(zh)
*
|
2012-02-17 |
2017-06-06 |
艾伯维公司 |
用作人呼吸道合胞病毒（rsv）抑制剂的二氨基嘧啶
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
TWI485146B
(zh)
*
|
2012-02-29 |
2015-05-21 |
Taiho Pharmaceutical Co Ltd |
Novel piperidine compounds or salts thereof
|
|
MX2014011115A
(es)
|
2012-03-16 |
2015-03-13 |
Axikin Pharmaceuticals Inc |
Inhibidores de 3,5-diaminopirazol cinasa.
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
RS61664B1
(sr)
|
2012-04-24 |
2021-04-29 |
Vertex Pharma |
Inhibitori dna-pk
|
|
CA2875990A1
(en)
*
|
2012-05-24 |
2013-11-28 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as tyk2 inhibitors
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
CA2878621C
(en)
*
|
2012-07-10 |
2020-09-15 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
|
US9555115B2
(en)
*
|
2012-09-19 |
2017-01-31 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition for oral administration with improved dissolution and/or absorption
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
CN103191120B
(zh)
*
|
2012-12-31 |
2015-11-25 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
|
|
CN103202843B
(zh)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
|
|
CN103059002B
(zh)
*
|
2012-12-31 |
2015-04-22 |
中山大学 |
具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
|
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
|
SI3527563T1
(sl)
|
2013-03-12 |
2022-01-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji DNA-PK
|
|
PE20151939A1
(es)
|
2013-03-14 |
2016-01-08 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
|
|
EP2968322B1
(en)
|
2013-03-15 |
2018-12-26 |
The Trustees of Columbia University in the City of New York |
Map kinase modulators and uses thereof
|
|
JP6360881B2
(ja)
|
2013-03-22 |
2018-07-18 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
KR20160099081A
(ko)
|
2013-07-26 |
2016-08-19 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조합 방법
|
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
SI3424920T1
(sl)
|
2013-10-17 |
2020-08-31 |
Vertex Pharmaceuticals Incorporated |
Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
|
|
ES2676734T3
(es)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2015103355A1
(en)
|
2014-01-01 |
2015-07-09 |
Medivation Technologies, Inc. |
Compounds and methods of use
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
EP3777833B1
(en)
|
2014-03-13 |
2023-10-18 |
Neuroderm Ltd. |
Dopa decarboxylase inhibitor compositions
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
置換されたヘテロアリール化合物および使用方法
|
|
MA39840B1
(fr)
|
2014-04-04 |
2020-10-28 |
Iomet Pharma Ltd |
Dérivés indolés destinés à être utilisés dans le domaine de la médecine
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
HRP20250213T1
(hr)
|
2014-10-13 |
2025-04-25 |
Yuhan Corporation |
Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
|
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
WO2016123627A1
(en)
*
|
2015-01-30 |
2016-08-04 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
|
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
|
DK3303348T3
(da)
|
2015-05-28 |
2019-11-11 |
Theravance Biopharma R&D Ip Llc |
Naphthyridinforbindelser som JAK-kinaseinhibitorer
|
|
JP2018135268A
(ja)
*
|
2015-06-05 |
2018-08-30 |
大日本住友製薬株式会社 |
新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
|
|
US20180207173A1
(en)
|
2015-07-21 |
2018-07-26 |
Millennium Pharmaceuticals, Inc. |
Administration of aurora kinase inhibitor and chemotherapeutic agents
|
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
EA201800367A1
(ru)
*
|
2015-12-10 |
2019-02-28 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Способы лечения болезни хантингтона
|
|
CN105384702B
(zh)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
三取代均三嗪类化合物及其制备方法
|
|
CN105399695B
(zh)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
三嗪类化合物及其制备方法和用途
|
|
CN105503754B
(zh)
*
|
2015-12-11 |
2017-11-17 |
浙江大学 |
2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
|
|
US10894784B2
(en)
|
2015-12-18 |
2021-01-19 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
AU2017233841B9
(en)
|
2016-03-14 |
2021-09-09 |
Afferent Pharmaceuticals Inc. |
Pyrimidines and variants thereof, and uses therefor
|
|
KR102377805B1
(ko)
|
2016-03-25 |
2022-03-22 |
애퍼런트 파마슈티컬스 인크. |
피리미딘 및 그의 변이체, 및 그의 용도
|
|
AU2017258186B2
(en)
|
2016-04-28 |
2020-09-17 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine compounds as JAK kinase inhibitors
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
KR20190062485A
(ko)
|
2016-09-27 |
2019-06-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
|
|
US10858319B2
(en)
|
2016-10-03 |
2020-12-08 |
Iomet Pharma Ltd. |
Indole derivatives for use in medicine
|
|
WO2018089546A1
(en)
*
|
2016-11-08 |
2018-05-17 |
Vanderbilt University |
Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
CN108239071B
(zh)
*
|
2016-12-27 |
2020-12-04 |
沈阳药科大学 |
酰胺及硫代酰胺类衍生物及其制备方法和应用
|
|
FR3064275B1
(fr)
|
2017-03-21 |
2019-06-07 |
Arkema France |
Procede de chauffage et/ou climatisation d'un vehicule
|
|
AU2018278714B2
(en)
|
2017-05-30 |
2022-06-02 |
Basf Se |
Pyridine and pyrazine compounds
|
|
KR20200033249A
(ko)
|
2017-06-05 |
2020-03-27 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료 화합물
|
|
US11395822B2
(en)
|
2017-06-28 |
2022-07-26 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's disease
|
|
CA3067591A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
|
ES2969536T3
(es)
|
2017-06-30 |
2024-05-21 |
Beijing Tide Pharmaceutical Co Ltd |
Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
|
|
JP2020525525A
(ja)
*
|
2017-06-30 |
2020-08-27 |
ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
|
|
WO2019000683A1
(zh)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
EP3676264A1
(en)
*
|
2017-08-28 |
2020-07-08 |
Acurastem Inc. |
Pikfyve kinase inhibitors
|
|
CN111683662B
(zh)
*
|
2017-08-28 |
2024-04-02 |
陈志宏 |
取代嘧啶类化合物及其药物组合物和治疗方法
|
|
AU2018354370B2
(en)
|
2017-10-27 |
2023-04-27 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine compound as JAK kinase inhibitor
|
|
CA3076444A1
(en)
*
|
2017-11-23 |
2019-05-31 |
Biomed X Gmbh |
Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
|
|
EP3720560A4
(en)
*
|
2017-12-06 |
2022-01-05 |
Ludwig Institute for Cancer Research Ltd |
METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
|
|
CA3093802A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
US12103926B2
(en)
|
2018-03-27 |
2024-10-01 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
AU2019295632B2
(en)
*
|
2018-06-25 |
2025-03-06 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
|
EA202092899A1
(ru)
|
2018-06-27 |
2021-05-14 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Гетероарильные соединения для лечения болезни гентингтона
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
BR112020026545A2
(pt)
|
2018-06-27 |
2021-03-23 |
Ptc Therapeutics, Inc. |
Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
|
|
MX2021006283A
(es)
*
|
2018-11-30 |
2021-10-22 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
|
|
JP7660063B2
(ja)
|
2018-12-28 |
2025-04-10 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
|
|
AR118768A1
(es)
|
2019-04-24 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
Derivados de pirimidina como inhibidores de las cinasas jak
|
|
HRP20241053T1
(hr)
|
2019-04-24 |
2024-11-08 |
Theravance Biopharma R&D Ip, Llc |
Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti
|
|
KR20220042159A
(ko)
|
2019-08-01 |
2022-04-04 |
인테그랄 바이오사이언스 피브이티. 엘티디. |
키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
|
|
CN114667289B
(zh)
|
2019-09-18 |
2025-08-26 |
武田药品工业有限公司 |
杂芳基血浆激肽释放酶抑制剂
|
|
ES2987744T3
(es)
|
2019-09-18 |
2024-11-18 |
Takeda Pharmaceuticals Co |
Inhibidores de calicreína plasmática y usos de los mismos
|
|
CN110483493A
(zh)
*
|
2019-09-19 |
2019-11-22 |
广东工业大学 |
一种二唑类衍生物及其制备方法和应用
|
|
CN115209952B
(zh)
|
2020-01-13 |
2025-05-30 |
维基分析有限公司 |
经取代的吡唑并嘧啶及其用途
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
US20240199613A1
(en)
*
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
WO2022204721A1
(en)
*
|
2021-03-26 |
2022-09-29 |
Sumitomo Pharma Oncology, Inc. |
Alk-5 inhibitors and uses thereof
|
|
EP4337198A4
(en)
|
2021-05-11 |
2025-04-16 |
Oric Pharmaceuticals, Inc. |
POLO-TYPE 4 KINASE INHIBITORS
|
|
CA3223223A1
(en)
|
2021-06-28 |
2023-01-05 |
Blueprint Medicines Corporation |
Cdk2 inhibitors
|
|
KR102692529B1
(ko)
*
|
2021-07-01 |
2024-08-08 |
한국원자력의학원 |
Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN116354938B
(zh)
*
|
2021-12-28 |
2024-02-20 |
沈阳药科大学 |
一类喹唑啉衍生物与其类似物的制备方法及应用
|
|
CN114276302B
(zh)
*
|
2022-01-11 |
2023-07-25 |
山东百启生物医药有限公司 |
一种制备2,4-二氨基喹唑啉衍生物的方法
|
|
CN116813595B
(zh)
*
|
2022-03-28 |
2025-07-18 |
上海医药工业研究院有限公司 |
喹唑啉类衍生物、其制备方法、药物组合物及应用
|
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
CN117736198A
(zh)
*
|
2022-09-21 |
2024-03-22 |
科辉智药生物科技(深圳)有限公司 |
大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
|
|
CN115403568B
(zh)
*
|
2022-09-21 |
2023-09-29 |
中山大学 |
一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
|
|
AU2024226381A1
(en)
*
|
2023-02-23 |
2025-10-09 |
Accutar Biotechnology, Inc. |
Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
|
|
US12161612B2
(en)
|
2023-04-14 |
2024-12-10 |
Neuroderm, Ltd. |
Methods and compositions for reducing symptoms of Parkinson's disease
|